Date: 2015-12-14
Type of information: Fundraising
Company: Seventure Partners (France)
Investors: Danone (France) MultiCap Croissance (France) Natixis (France) Novartis (Switzerland) Tereos (France) Tournier (France) Unigrains (France) Bel (France) Lesaffre (France)
Amount: € 160 million
Funding type: fundraising
Planned used: The aim of Health for Life Capital™ has been to support innovative high-growth entrepreneurial ventures. Initial investments have been made in Enterome Bioscience (Paris), LNC (Laboratoires Nutrition & Cardiométabolisme) (Bordeaux), Interface Therapeutics (California, USA), Humedics (Berlin), and most recently, in January 2015, MaaT Pharma (Lyon), a newly founded French microbiome company. The geographical focus of Health for Life Capital™ is primarily in Europe, but also extends to North America and Asia. Investment is focused on four areas: microbiome, nutrition, biotech and digital health.
Others: * On December 14, 2015, Seventure Partners announced the final closing of its Health for Life Capital™ at €160 million. This fund that focusses primarily on microbiome-based biotech and nutrition innovations brings together a broad network of industrial partners., Danone, Tereos, Lesaffre, Bel, Tornier, and now Novartis. * On March 19, 2015, Seventure announced that it has received further investment in its Health for Life Capital™, the largest fund worldwide that focusses primarily on microbiome-based biotech and nutrition innovations. The fund raising has attracted both financial investors, strategic investors and serial entrepreneurs. When Health for Life Capital™ was launched, Seventure stated its intention to raise €120m (USD130m). Currently the fund stands at €100m (USD109m), but with more interested investors lined up, Seventure is en route to approach the full target amount. The Health for Life Capital investment vehicle is composed of a Luxembourg SICAR and a French FPCI (AIF fund). Seventure Partners acts as an Investment Advisor of the SICAR (Health for Life Management) General Partner, and as the Management Company of the FPCI. * On January 20, 2014, Seventure Partners has announced the launch of its new fund: Health for Life Capital. This €120m fund is dedicated to health (biotech, medtech, diagnostic…), connected health, nutrition, and the recent game-changing discoveries related to the microbiome and its applications in all fields. It will invest in innovative companies with high growth potential mainly in Europe but will also look to expand in in North America and Asia. Appointed CEO in Oct. 2011, Isabelle de Cremoux led this fund raising. She has been heading the Life Science team since 2001 and is the force behind the strategic positioning of Seventure Partners in these fields. The fund has attracted industrial and financial investors like Danone, Natixis, Tereos, Tornier and Unigrains. New future closings are also anticipated in the coming months.
Therapeutic area:
